TAKING AIM AT FOOD ALLERGIES
Aimmune Therapeutics is a biopharmaceutical company developing
and bringing new treatments to people with food-mediated
conditions and potentially life-threatening food allergies.
We are on a mission to transform the lives of millions of
people who live with serious food allergies.
Our vision is to help those living with food allergies by
providing the means necessary to avoid potential reactions
due to accidental exposures.
The Power of a Shared Vision
Aimmune Therapeutics was founded directly in response to a united call to action by leading stakeholders in food allergy. In 2011, a group of parents, patient advocacy organisations, leading clinical and academic physicians, and the pharmaceutical industry came together and concluded there was a significant need for the development of food allergy treatments. Recognising that developing and commercialising a novel therapy required specialised expertise and a dedicated business structure, Aimmune Therapeutics was established (originally called Allergen Research Corporation).
Building on more than a century of research on oral immunotherapy for food allergy, Aimmune uses rigorous science and a structured approach to develop complex biologic immunotherapies that combine the rigor of a regulated medication with well-characterised allergen profiles.
In October 2020, Aimmune Therapeutics was acquired by Nestlé Health Science, a recognised leader in the field of nutritional science.
“Our goal is to help patients and their families live without the fear of accidental reactions to food. We aim to become a global leader in developing therapies and solutions for people with food allergies, intolerances, and their associated conditions.”